Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2026-01-19 @ 11:28 AM
Study NCT ID:
NCT04195750
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-29
First Post:
2019-12-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
6482-005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None